Tuesday, April 22, 2014

PRESIDENT OF LEADING SOUTH KOREAN BIOPHARMACEUTICAL COMPANY GREEN CROSS HOLDINGS JOINS STEMEDICA’S BOARD OF DIRECTORS

(Source: April 22; San Diego)

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross, whose recent investment closed Stemedica’s Series B funding round, is one of the world’s largest vaccine and plasma product manufacturers, and the company’s influence in Asia, China and the United States spans advanced research and development, biotech manufacturing and product development. Dr. Rhee’s addition to Stemedica’s board supports both companies’ shared vision of moving stem-cell technologies from clinical trials into worldwide medical practice.
“Stemedica is honored to add the President of Green Cross Holdings to our board of directors,” says Roger A. Howe, Ph.D., Executive Chairman of Stemedica. “Dr. Rhee is one of few industry leaders who has a proven track record for bringing innovative new technologies from clinical trials to mainstream medical practice. His expertise will help Stemedica set new standards for stem cell quality and affordability on a global scale.”
BG Rhee
Dr. Byung-Geon Rhee
President Green Cross Holdings
“Green Cross conducted extensive due diligence on stem cell technologies before making the investment to close Stemedica’s funding round,” says Dr. Byung-Geon Rhee, President of Green Cross Holdings. “The more we learned about Stemedica, the more we wanted to participate in its next phase of growth. I am happy to have the opportunity to serve as a member of Stemedica’s board of directors.”
Dr. Rhee has more than 27 years of experience in bio industry. For the past 10 years, he has served in executive-level roles at Green Cross Corp. and now parent company Green Cross Holdings. Before joining the South Korean market leader, he founded United States-based gene-therapy company Expression Genetics, Inc. in 2002. He has also served as Samyang Corp.’s pharmaceutical business unit head and LG Chem’s drug-development division head. He is currently Chairman of Korea Biotechnology Industry Organization (BIO), Co-President for two forums within the South Korea Ministry of Health and Welfare: Health Technology Forum and Infectious Disease R&D Forum. He is member of the National Academy of Engineering of Korea. He earned his B.Sc. and M.Sc. in chemical engineering from Seoul National University, his Ph.D. in chemical/biomedical engineering from Rice University and completed post-doctoral work at the University of Wisconsin, Madison.
About Green Cross
Green Cross is the largest biopharmaceutical company in Korea. Green Cross provides safe and effective healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, Green Cross specializes in the development and manufacture of plasma-derivatives, preventive vaccines, recombinant proteins, therapeutic antibodies and cell therapies. The company can be found online at www.greencross.com.
About Stemedica Cell Technologies Inc. 
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class, allogeneic, adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government-licensed manufacturer of clinical-grade stem cells and is approved by the FDA for clinical trials in acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult, allogeneic stem cells. The company has headquarters in San Diego, Calif., and can be found online at www.stemedica.com. .
All media inquiries:
Kimberly Stoddard
The Townsend Team
415.806.5793
kimberly@townsendteam.com

Monday, April 14, 2014

STEMEDICA APPOINTS NIH CENTER FOR REGENERATIVE MEDICINE FORMER FOUNDING DIRECTOR DR. MAHENDRA RAO TO ITS SCIENTIFIC AND MEDICAL ADVISORY BOARD

Renowned Stem Cell and Regenerative Medicine Authority Will Help Stemedica in Its Plans to Meet the Global Demand for Stem Cell Technology

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes to its Scientific and Medical Advisory Board prominent stem cell and regenerative medicine expert Dr. Mahendra Rao, M.D., Ph.D. As a Founding Director of the National Institute of Health (NIH) Center for Regenerative Medicine (CRM), he has built the Center into a world-class organization recognized for its excellence in the clinical translation of stem cell technology, and his expertise will help Stemedica shape its strategy to meet global demand for its stem cell technology.

“I look forward to a long and beneficial relationship with Stemedica,” Dr. Mahendra Rao says. “In my various professional assignments and industry engagements, I have had an opportunity to extensively review the stem cell technology that is available in the marketplace. I decided to join the Stemedica team because Stemedica has developed an elegant manufacturing process and is committed to cell based therapies for multiple medical diseases that are difficult to treat.”

Dr. Rao is internationally renowned for his research in stem cells and regenerative medicine. He has worked in the stem cell field for more than 20 years, with positions in academia, government, regulatory affairs and industry, and he has authored more than 300 publications. He received his M.D. from Bombay University and his Ph.D. in developmental neurobiology from the California Institute of Technology. Following postdoctoral training at Case Western Reserve University, he established his research laboratory in neural development at the University of Utah. He next joined the National Institute on Aging as Chief of the Neurosciences Section where he studied neural progenitor cells. Most recently, he was Vice President of Regenerative Medicine at Life Technologies.
“We are very fortunate to have someone of Dr. Rao’s caliber join the Stemedica Team,” says Maynard A. Howe, Ph.D., Vice Chairman and CEO of Stemedica. “His experience and expertise are already proving invaluable as Stemedica strengthens its global leadership position in manufacturing multiple stem cell products for use in various clinical trials in the United States and internationally.”
Throughout his career, Dr. Rao has served internationally on advisory boards for companies involved in stem cell processing and translational applications. He has also participated on committees including Chairman of the U.S. Food and Drug Administration’s Cellular Tissue and Gene Therapies Advisory Committee, the California Institute of Regenerative Medicine, International Society for Stem Cell Research and as the liaison to the International Society for Cellular Therapy.
“Based on his extensive stem cell and regenerative medicine accomplishments, Dr. Rao is the ideal candidate to advise Stemedica during this period of rapid growth,” states Alex Kharazi, M.D., Ph.D., CTO of Stemedica Cell Technologies Inc.
About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class, allogeneic, adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government-licensed manufacturer of clinical-grade stem cells and is approved by the FDA for clinical trials in acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult, allogeneic stem cells. The company has headquarters in San Diego, Calif., and can be found online at www.stemedica.com 
All media inquiries:
Kimberly Stoddard
The Townsend Team
415.806.5793
kimberly@townsendteam.com

Wednesday, March 26, 2014

STEMEDICA ANNOUNCES INTERNATIONAL EDUCATIONAL COLLABORATION WITH SMART LIVING

(Source: March 26; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a specialty biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and Smart Living, a subsidiary of Smart Global, a $2 billion (USD) globally diversified conglomerate, are pleased to announce an international educational collaboration.
Smart Living currently organizes dynamic “One World” educational conferences designed to introduce breakthrough technologies and educational programs focused on health care and regenerative medicine to countries throughout the world. High profile leaders in medicine, science, business, education, government and community organizers are brought together at these international forums to participate in presentations, discussions and educational programs.
Stemedica, a global leader in regenerative medicine focused on stem cell research and clinical trials, has been selected to introduce breakthrough technologies in the dynamic field of stem cells and their role in translational medicine.
In addition to the educational outreach, Smart Living is making significant advances in health care with its Smart Health City model. This model, anticipated to go global, was developed to be an all-inclusive health care destination offering services including multispecialty hospitals, medical office buildings, medical rehabilitation centers, international patient care centers, medical education and training, clinical research, on campus staff residence, research and technology centers. The first of these Health Cities is on 15 acres located in Saket in the heart of Delhi, India.
Swati Saxena, MD, Programme Director at Smart Living said, “What makes Smart Living a unique concept is that it provides integrated and converged facilities where strong scientific evidence is paired with health and wellness initiatives in a step-by-step methodic fashion guided by medical experts.”
Dr. Bhupendra Kumar (“BK”) Modi, PhD, Chairman Smart Global and Founder of Smart Living said, “We are delighted to make an investment into, and to collaborate with, Stemedica. Our objective is to implement sophisticated technologies, advance new and improved innovations and encourage research for the betterment of the health of society. As Smart Living continues its worldwide educational efforts to promote health and wellbeing, Stemedica’s leadership in the regenerative medicine movement is an ideal fit for our efforts.”
Roger A. Howe, PhD, Stemedica’s Executive Chairman said about the collaboration, “This is an excellent opportunity to contribute to Dr. Modi’s “One World” educational forums. As an active participant in these forums, we will be able to promote healthier lifestyles in communities around the world. Stemedica, together with Smart Living, will emphasize the importance of new innovations that lead to medical breakthroughs in regenerative medicine, including Stemedica’s stem cell technologies.”
As part of the collaboration, Mr. Ozi Amanat, Smart Global Chief Investment Officer will become a business advisor to Stemedica. In accepting the appointment, Mr. Amanat said, “I’m honored to be working with Stemedica and its leadership. Stemedica is poised to bring the power and potential of regenerative medicine to the world. Stemedica’s leadership in this field is exciting and I look forward to supporting their continued growth as well as creating maximum value to both organizations.”
Smart Living has made an undisclosed investment in Stemedica.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
For more information regarding Stemedica Cell Technologies, Inc., please contact Dave McGuigan, Vice President of Marketing and Business Development: dmcguigan@stemedica.com
About Smart Global
Smart Global formerly Spice Global, is a $2 billion (USD) diversified conglomerate that encompasses a variety of businesses that harness speed, creativity and efficiency to invest, develop and market products that are defining how we live today. It currently serves over 25 million customers worldwide across various sectors – telecom, finance, entertainment technology and healthcare. Established by renowned global entrepreneur and futurepreneur, Dr. Bhupendra Kumar Modi, Spice Global has expanded its footprint across Los Angeles, San Francisco, New York, London, New Delhi, Bombay, Dubai, Kuala Lumpur in addition to China and Africa.
For further information regarding Smart Global, please contact Arem Mukim, Manager Brand & Communications:Arem.mukim@spiceglobal.com

Tuesday, February 18, 2014

STEMEDICA ISSUED U.S. PATENT METHOD FOR IDENTIFYING NEURIPOTENT CELLS

(Source: Feburary 18; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the Company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent and Trademark Office.
The Stemedica patent broadly covers a method for identifying the potency of a cell population, as it becomes neural cells, to engraft in the developing brain of a chick embryo. “This test contributes significantly to the screening of cells capable of engrafting and differentiating in vivo saving both time and valuable resources,” said Alex Kharazi, MD, PhD, Chief Technology Officer at Stemedica. “It is a simple, cost-effective test of neural stem cell potency using a chicken embryonic brain, and is an important and effective step forward in the evaluation and testing of neuripotent cells.”
The chick embryo brain approximates an adult brain. The patented transplant method distinguishes neuripotent stem cells from those which fail to engraft and differentiate into neurons. The method is used for identifying chemical and genetic factors in the manufacture of efficacious neural stem cells.
“In vitro propagated neural stem cells have shown great promise in treating neurodegenerative diseases due to their migratory ability and their multipotency, that is, their ability to differentiate into neural and glial cell lineages,” noted Maynard Howe, PhD, CEO of Stemedica. “Unfortunately, these important features are often lost during tissue culture and expansion and therefore it is critically important to ascertain that expanded neural stem cells retain their potency”.
The method is used to screen candidate neuripotent cells lines for master banking; validation of working cells banks; and, identifying agents and conditions capable of inducing neural differentiation in a cell population.
The patented method was reported in the Journal of Neurosurgery, March 1, 2013 (DOI: 10.3171/2013.1.JNS12698) entitled,“Chicken embryonic brain: an in vivo model for verifying neural stem cell potency” (Kharazi, Alex., et al.). The main objective of the study was to determine whether the in vitro multi-lineage differentiation of human neural stem cells would correlate with their ability to engraft in the developing brain.
“This method gives the biomedical and drug discovery industries the opportunity to significantly reduce animal testing of biologics and drugs. In particular, Stemedica can evaluate the potency of stem cells in vivo in the cleanroom and laboratory setting thus eliminating the requirement of animal testing at outside facilities,” noted Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica. “The method supports Stemedica‘s development of cells and cell products for the treatment of neural degenerative and traumatic disorders of the central nervous system.”
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
Media Contact for Stemedica: Dave McGuigan at dmcguigan@stemedica.com

Monday, February 17, 2014

NEW PHASE IIA TRIAL IN THE UNITED STATES AND PHASE III TRIAL IN KAZAKHSTAN STUDY THE USE OF CARDIOCELL’S ITMSC THERAPY FOR TREATING ACUTE MYOCARDIAL INFARCTION

The Only AMI Clinical Trials Using Ischemia-Tolerant Mysenchymal Stem Cells (itMSCs) Enter Next Phase Based on Successful Previous Studies
(Source: Feburary 17; Cardio Cell)
CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually. In the United States, CardioCell is initiating a Phase IIa AMI clinical trial to evaluate the clinical safety and efficacy of its itMSCs. In addition, the Ministry of Health in Kazakhstan is beginning a Phase III AMI clinical trial on the intravenous administration of CardioCell’s itMSCs, based on the efficacy and safety found in Phase II clinical trials.
Only CardioCell’s AMI therapies feature itMSCs, which are exclusively licensed from CardioCell’s parent company Stemedica Cell Technologies Inc. Unlike all other MSCs – which are grown under normoxic conditions – itMSCs are grown under hypoxic conditions that more closely resemble the environment in which they live in the body. These bone-marrow-derived, allogeneic, mesenchymal stem cells are unique because they are grown under chronic hypoxic conditions and are ischemia-tolerant. Compared to other MSCs, itMSCs secrete higher levels of growth factors usually associated with angiogenesis and healing. The current studies have been designed to help determine if CardioCell’s itMSC-based therapies stimulate a regenerative response in AMI patients.
“CardioCell’s new Phase IIa AMI study is built on the excellent safety data reported in previous Phase I clinical trials using our unique, hypoxically grown stem cells,” says Dr. Sergey Sikora, Ph.D., CardioCell’s president and CEO. “We are also pleased to report that the Ministry of Health in Kazakhstan is proceeding with a Phase III CardioCell-therapy study following its Phase II study that was highly promising in terms of efficacy and safety. Our studies target AMI patients who have depressed left ventricular ejection fraction (LVEF), which makes them prone to developing extensive scarring and therefore to the development of chronic heart failure. CardioCell hopes our itMSC therapies will inhibit the development of extensive scarring and, thus, the occurrence of chronic heart failure in these patients.”
Taking place at Emory University, Sanford Health and Mercy Gilbert Medical Center, CardioCell’s Phase IIa AMI trial is a double-blinded, multicenter, randomized study to assess the safety, tolerability and preliminary clinical efficacy of a single, intravenous dose of allogeneic mesenchymal bone-marrow cells to subjects with ST segment-elevation myocardial infarction (STEMI).
“While stem-cell therapy for cardiovascular disease is nothing new, CardioCell is bringing to the field a new, unique type of stem-cell technology that has the possibility of being more effective than other AMI treatments,” says MedStar Heart Institute’s Director of Translational and Vascular Biology Research and CardioCell’s Scientific Advisory Board Chair Dr. Stephen Epstein. “Evidence exists demonstrating that MSCs grown under hypoxic conditions express higher levels of molecules associated with angiogenesis and healing processes. There is also evidence indicating they migrate with greater avidity to various cytokines and growth factors and, most importantly, home more robustly to ischemic tissue. Studies like those underway using CardioCell’s technology are designed to determine if we can evoke a more potent healing response that will reduce the extent of myocardial cell death occurring during AMI and thereby decrease the amount of scar tissue resulting from the infarct. A therapy that could achieve this would have a major beneficial impact in reducing the occurrence of chronic heart failure.”
In addition to the United States study, Kazakhstan’s National Scientific Medical Center is conducting a Phase III AMI clinical trial using CardioCell’s itMSCs, which are sponsored by local licensee Altaco. This study, “Intravenous Administration of itMSCs for AMI Patients,” is proceeding based on a completed Phase II efficacy and safety study. Results for that Phase II study are preliminary because the sample group was so small, but the findings demonstrated statistically significant elevation (more than 12 percent over the control group) in LVEF and reduction in inflammation, as suggested by lower CRP (C-reactive protein) levels in treatment verse control groups. Thus, Dr. Daniyar Jumaniyazov, M.D., Ph.D., principal investigator in Kazakhstan clinical trials states: “In our clinical Phase II trial for patients with AMI, treatment using itMSCs improved global and local myocardial function and normalized systolic and diastolic left ventricular filling, as compared to the control group. We are encouraged by these results and look forward to confirming them in a Phase III study.”
CardioCell’s treatment is the first to apply itMSC therapies for cardiovascular indications like AMI, chronic heart failure and peripheral artery disease. Manufactured by CardioCell’s parent company Stemedica and approved for use in clinical trials, itMSCs are manufactured under Stemedica’s patented, continuous-low-oxygen conditions and proprietary media, which provide itMSCs’ unique benefits: increased potency, safety and scalability. itMSCs differ from competing MSCs in two key areas. itMSCs demonstrate increased migratory ability towards the place of injury, and they show increased secretion of growth and transcription factors (e.g., VEGF, FGF and HIF-1), as demonstrated in a peer-reviewed publication (Vertelov et al., 2013). This can potentially lead to improved regenerative abilities of itMSCs. In addition, itMSCs have significantly fewer HLA-DR receptors on the cell surface than normal MSCs, which might reduce the propensity to cause immune responses. As another benefit, itMSCs are highly scalable. A single donor specimen can currently yield about 1 million patient treatments, and this number is expected to grow to 10 million once full robotization of Stemedica’s facility is complete. Visit our website for more information about our itMSC technology and other clinical trials in process.
About CardioCell, LLC Founded in San Diego, Calif., in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the former Soviet Union, Europe and the United States. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.

Wednesday, February 12, 2014

STEMEDICA ANNOUNCES NEW BOARD MEMBER AND CHAIRMAN OF AUDIT COMMITTEE

(Source: February 12 2014; Stemedica Cell Technologies, Inc.)
Stemedica announced today that Richard Mejia, Jr. has joined the Company’s Board of Directors and will be Chairman of the Company’s Audit Committee effective January 31, 2014.
Mr. Mejia spent 38 years with Ernst & Young, LLP where he was a partner for 25 years. He spent the last eight years exclusively serving life science companies and as a Life Science Industry leader for his firm. Mr. Mejia has extensive experience in securities filings and offerings and other strategic transactions. “Rich’s extensive experience as a leader in the life sciences practice at Ernst & Young provides Stemedica with the kind of seasoned leadership we are pursuing,” stated Roger Howe, PhD, Stemedica’s Executive Chairman. Mr. Mejia is also an experienced director and Audit Committee member for both healthcare and technology companies.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
Media Contact for Stemedica: Dave McGuigan at dmcguigan@stemedica.com

Monday, January 27, 2014

STEMEDICA ANNOUNCES NEW CHIEF FINANCIAL OFFICER

(Source: January 27 2014; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc. a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Craig W. Carlson has been appointed the Company’s Chief Financial Officer effective March, 2014.
Craig Carlson brings 34 years of financial, accounting, investor relations, and operational experience specifically in the biotech and biopharmaceutical industries to his role at Stemedica. Over the past 21 years of his career, Craig has played an integral role in raising over $420 million from private and public markets and has also had significant international experience having been responsible for various subsidiaries in China, Korea and the United Kingdom.
“Craig’s solid background in financial and accounting management along with his experience in SEC reporting, investor relations and in supporting financing initiatives in emerging growth companies is well-suited for Stemedica,” said Roger Howe, PhD, Stemedica’s Executive Chairman. “I have confidence that under Craig’s leadership, Stemedica will continue to improve our operating and financial efficiency and continue to create shareholder value.”
Previously, Craig was the Senior Vice President, Chief Financial Officer and Secretary at Talon Therapeutics, a specialty biopharmaceutical company, where he was responsible for all finance, accounting, SEC filings, information technology, and intellectual property with financial oversight on clinical trials. During his time at Talon he played an integral role in securing $100 million in financing; managed the Goldman Sachs mergers and acquisitions efforts; updated and streamlined Sarbanes Oxley controls and procedures; renegotiated licensing and royalty agreements, and actively participated in positioning the company for sale to Spectrum Pharmaceuticals in 2013.
He served a similar role as Senior Vice President, Chief Financial and Operating Officer as well as Managing Director U.K. for Cygnus Inc., a medical device company focused on manufacturing transdermal drug delivery systems and non-invasive glucose monitoring devices. At Cygnus, Craig supported the raise of more than $250 million from public and private markets as well as commercial partner payments. He also led the licensing negotiations for U.S. sales and distribution agreements as well as the national launch of the world’s first non-invasive glucose monitoring device. In addition, he initiated an aggressive investor relations marketing program that contributed to a tenfold increase in the company’s valuation. He also played a significant supporting role in the company’s sale of their transdermal patch business division to Johnson & Johnson.
During his tenure at Neurobiological Technologies, a biotech company focused on Phase III trials for Ischemic Stroke, he was instrumental in raising over $70 million in the midst of a difficult funding environment; successfully remedying two years of financial restatements from prior management; instituted new budgeting and cash flow forecasting systems; and led contract negotiations with CROs (Contract Research Organizations) and strategic partners.
Craig has an MBA from Stanford University Graduate School of Business, MS Ed. Counseling from Hofstra University and a BA in Political Science from Union College.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
Media Contact for Stemedica: Dave McGuigan at dmcguigan@stemedica.com